Literature DB >> 26168997

Dosing profile profoundly influences nicotinic acid's ability to improve metabolic control in rats.

Tobias Kroon1, Ann Kjellstedt2, Pia Thalén2, Johan Gabrielsson3, Nicholas D Oakes2.   

Abstract

Acute nicotinic acid (NiAc) administration results in rapid reduction of plasma FFA concentrations. However, sustained NiAc exposure is associated with tolerance development resulting in return of FFA to pretreatment levels. The aim of this study was to determine whether a 12 h rectangular exposure profile (intermittent dose group) could avoid tolerance development and thereby reverse insulin resistance induced by lipid overload. FFA lowering was assessed in male Sprague Dawley (lean) and obese Zucker rats (obese) in response to a 5 h NiAc infusion, in either NiAc-naïve animals or after 5 days of continuous (24 h/day) or intermittent (12 h/day) NiAc dosing (via implantable, programmable minipump). We found that intermittent dosing over 5 days preserved NiAc-induced FFA lowering, comparable to dosing in NiAc-naïve animals. By contrast, following 5 days continuous administration, NiAc-induced FFA lowering was lost. The effect of intermittent NiAc infusion on insulin sensitivity was assessed in obese Zucker rats using hyperinsulinemic-isoglycemic clamps. The acute effect of NiAc to elevate glucose infusion rate (vs. saline control) was indeed preserved with intermittent dosing, while being lost upon continuous infusion. In conclusion, an intermittent but not continuous NiAc dosing strategy succeeded in retaining NiAc's ability to lower FFA and improve insulin sensitivity in obese Zucker rats.-Kroon, T., A. Kjellstedt, P. Thalén, J. Gabrielsson, and N. D. Oakes.
Copyright © 2015 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  GPR109A; adipose tissue; diabetes; drug therapy/hypolipidemic drugs; insulin; lipolysis and fatty acid metabolism; niacin; tachyphylaxis

Mesh:

Substances:

Year:  2015        PMID: 26168997      PMCID: PMC4548772          DOI: 10.1194/jlr.M058149

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  47 in total

Review 1.  Quantitative pharmacology or pharmacokinetic pharmacodynamic integration should be a vital component in integrative pharmacology.

Authors:  J Gabrielsson; A R Green
Journal:  J Pharmacol Exp Ther       Date:  2009-09-24       Impact factor: 4.030

2.  Elevation of fasting morning glucose relative to hemoglobin A1c in normoglycemic patients treated with niacin and with statins.

Authors:  Veena Rajanna; Kristen B Campbell; Jeffrey Leimberger; Bibhu D Mohanty; John R Guyton
Journal:  J Clin Lipidol       Date:  2011-12-23       Impact factor: 4.766

3.  Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.

Authors:  Nicholas D Oakes; Pia Thalén; Therese Hultstrand; Severina Jacinto; Germán Camejo; Boel Wallin; Bengt Ljung
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-10       Impact factor: 3.619

4.  Nicotinic acid inhibits glucose-stimulated insulin secretion via the G protein-coupled receptor PUMA-G in murine islet β cells.

Authors:  Hong-ming Li; Mei Zhang; Sheng-tao Xu; Di-zheng Li; Lin-yun Zhu; Si-wu Peng; Guo-qiang Chen; Pamela M Martin; Vadivel Ganapathy; Chi-ju Wei
Journal:  Pancreas       Date:  2011-05       Impact factor: 3.327

5.  Glucose tolerance and plasma insulin in man during acute and chronic administration of nicotinic acid.

Authors:  T A Miettinen; M R Taskinen; R Pelkonen; E A Nikkilä
Journal:  Acta Med Scand       Date:  1969-10

Review 6.  The metabolic syndrome.

Authors:  Robert H Eckel; Scott M Grundy; Paul Z Zimmet
Journal:  Lancet       Date:  2005 Apr 16-22       Impact factor: 79.321

Review 7.  Free fatty acids and skeletal muscle insulin resistance.

Authors:  Edward W Kraegen; Gregory J Cooney
Journal:  Curr Opin Lipidol       Date:  2008-06       Impact factor: 4.776

8.  Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells.

Authors:  Nobumasa Hara; Kazuo Yamada; Tomoko Shibata; Harumi Osago; Tatsuya Hashimoto; Mikako Tsuchiya
Journal:  J Biol Chem       Date:  2007-06-29       Impact factor: 5.157

9.  Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.

Authors:  John R Guyton; Sergio Fazio; Adeniyi J Adewale; Erin Jensen; Joanne E Tomassini; Arvind Shah; Andrew M Tershakovec
Journal:  Diabetes Care       Date:  2012-02-14       Impact factor: 19.112

10.  The PPAR α / γ Agonist, Tesaglitazar, Improves Insulin Mediated Switching of Tissue Glucose and Free Fatty Acid Utilization In Vivo in the Obese Zucker Rat.

Authors:  Kristina Wallenius; Ann Kjellstedt; Pia Thalén; Lars Löfgren; Nicholas D Oakes
Journal:  PPAR Res       Date:  2013-10-27       Impact factor: 4.964

View more
  6 in total

1.  Nicotinic acid timed to feeding reverses tissue lipid accumulation and improves glucose control in obese Zucker rats[S].

Authors:  Tobias Kroon; Tania Baccega; Arne Olsén; Johan Gabrielsson; Nicholas D Oakes
Journal:  J Lipid Res       Date:  2016-11-15       Impact factor: 5.922

Review 2.  Regulation of hepatic glucose metabolism in health and disease.

Authors:  Max C Petersen; Daniel F Vatner; Gerald I Shulman
Journal:  Nat Rev Endocrinol       Date:  2017-07-21       Impact factor: 43.330

3.  Involvement of the metabolic sensor GPR81 in cardiovascular control.

Authors:  Kristina Wallenius; Pia Thalén; Jan-Arne Björkman; Petra Johannesson; John Wiseman; Gerhard Böttcher; Ola Fjellström; Nicholas D Oakes
Journal:  JCI Insight       Date:  2017-10-05

4.  Niacin promotes revascularization and recovery of limb function in diet-induced obese mice with peripheral ischemia.

Authors:  Dominic K T Pang; Zengxuan Nong; Brian G Sutherland; Cynthia G Sawyez; Debra L Robson; Jelena Toma; J Geoffrey Pickering; Nica M Borradaile
Journal:  Pharmacol Res Perspect       Date:  2016-04-14

5.  Modeling of free fatty acid dynamics: insulin and nicotinic acid resistance under acute and chronic treatments.

Authors:  Robert Andersson; Tobias Kroon; Joachim Almquist; Mats Jirstrand; Nicholas D Oakes; Neil D Evans; Michael J Chappel; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-21       Impact factor: 2.745

Review 6.  Lipid and glucose metabolism in white adipocytes: pathways, dysfunction and therapeutics.

Authors:  Pauline Morigny; Jeremie Boucher; Peter Arner; Dominique Langin
Journal:  Nat Rev Endocrinol       Date:  2021-02-24       Impact factor: 43.330

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.